Cambrex completed an investment project at its facility in Tallinn, Estonia to upgrade its kilogram-scale lab for the manufacture of pharmaceutical intermediates under current good manufacturing practice (CGMP) conditions.
 
The project includes the installation of a new 160-liter reactor train, which will expand the site’s capabilities to manufacture material for clinical trials and allow early phase projects to be developed further at the site prior to tech transfer and scale up. Building work and installation of the new reactor and supporting equipment is now complete, and preparation for GMP qualification is underway.
 
The facility also houses 150-liter glass and stainless-steel reactors, which will continue to offer kilogram-scale manufacturing of materials for pre-clinical toxicological study applications.
 
“Our team of experts in Tallinn work closely with the Cambrex manufacturing site at Karlskoga in Sweden, and this expansion will accelerate the progression and tech transfer of projects within the early clinical development phases,” commented Joe Nettleton, President of Cambrex’s Drug Substance Business Unit. He added, “Cambrex has a commitment to investing in the capacity, capabilities and expertise within our global network of facilities, to reinforce our position as a market-leading CDMO in small molecule development, and ensure we can serve the needs of the growing market.
 
The site in Tallinn provides custom organic synthesis and contract research, analytical and development services, working on process development and scale-up synthesis to kilogram quantities. The facility is located adjacent to Tallinn University of Technology’s campus, allowing for collaboration with the University’s analytical and chemistry departments.